



**Quarterly Information – ITR Interim  
Financial Statements – March 31, 2026 and  
Independent auditor’s review report**

## **Contents**

<b>Management Report</b> .....	4
<b>Message from the Board</b> .....	4
<b>Financial performance</b> .....	5
<b>Balance sheet</b> .....	7
<b>Statement of income for the year (DRE)</b> .....	9
<b>Statement of Comprehensive Income</b> .....	10
<b>Statement of changes in shareholders' equity</b> .....	11
<b>Statement of cash flows</b> .....	12
<b>Statement of Added Value</b> .....	13
<b>Notes to the quarterly information - ITR</b> .....	14
<b>1. Operations</b> .....	14
<b>a) General information</b> .....	14
<b>b) Manufacturing Unit and Certifications</b> .....	14
<b>c) Business Model and Strategic Partnerships</b> .....	14
<b>d) Partnerships for Productive Development (PDP)</b> .....	14
<b>2. Basis for preparation and presentation of quarterly information (ITR)</b> .....	14
a. Statement of conformity .....	15
b. Basis of preparation .....	15
c. Functional currency and presentation .....	15
d. Notes presented in the annual financial statements that are not presented in this interim financial information	15
<b>3. Consolidation</b> .....	16
<b>4. Cash and cash equivalents</b> .....	16
<b>5. Interest earning bank deposits</b> .....	17



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

<b>6. Accounts receivable</b> .....	17
<b>7. Inventories</b> .....	19
<b>8. Recoverable taxes</b> .....	19
<b>9. Advance to Supplier</b> .....	20
<b>10. Investments</b> .....	20
<b>11. Property, plant and equipment</b> .....	22
<b>12. Intangible assets</b> .....	23
<b>13. Suppliers</b> .....	25
<b>14. Securities payable</b> .....	26
<b>15. Loans and financing</b> .....	26
<b>16. Related parties</b> .....	27
<b>17. Income taxes - Income tax and social contribution</b> .....	28
<b>18. Contingencies</b> .....	30
<b>19. Long-term incentive</b> .....	31
<b>20. Shareholders' equity</b> .....	32
<b>21. Net revenues</b> .....	33
<b>22. Costs per type</b> .....	33
<b>23. General, administrative and other expenses</b> .....	33
<b>24. Financial revenues and expenses</b> .....	34
<b>25. Earning (loss) per share</b> .....	35
<b>26. Financial instruments and risk management</b> .....	35
<b>27. Transactions that do not involve cash or cash equivalents</b> .....	39
<b>28. Subsequent events</b> .....	40



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

## Management Report

Biommm S.A. (“Biommm” or “Company”; B3: “BIOM3”) announces its results for the first quarter of 2026.

This document was prepared based on individual and consolidated Quarterly Information (ITR) of Biommm S.A. for the quarter ended March 31, 2026, and prepared in accordance with Technical Pronouncement CPC 21 (RI) - Interim Statement and with International Standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the presentation of this information in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to the preparation of the Quarterly Information (ITR), accompanied by the independent auditors’ report.

## Message from Management

The first quarter of 2026 marks a historic milestone for Biommm S.A., confirming that the profitability trajectory achieved in 2025 is sustainable and consistent. We closed the period with net income of R\$ 9.7 million, a direct result of the maturation of our biotechnology platform in Nova Lima and the accuracy of the execution of our operational plan.

The strategic relevance of Biommm in the Brazilian health system continued to strengthen at the beginning of this year. The continuity and expansion of the supply of biomedicines for the private and public markets, with a range of clients that includes pharmacy chains and local distributors as well as the Ministry of Health, with centralized purchases and Productive Development Partnerships (PDPs). This diversity contributes to the resilience of our business model. We reinforce our position as a key player in the supply of insulins, with predictable revenues and long-term contracts that contribute to national autonomy in the supply of strategic medicines to the Brazilian population.

Operationally, 1Q26 was characterized by strong performance and efficiency gains. While our net revenue expanded 134% over the same period of last year, we maintained strict financial discipline to limit the growth of operating expenses to 13%. Our disciplined management allowed gross income to grow by 363%, with absorption of the fixed cost structure, resulting in an EBITDA of R\$ 12.4 million, nearly 4 times higher than the EBITDA achieved in the entire year 2025, and a healthy level of profitability to continue strengthening our capital structure.


### Perspectives and commitments

The beginning of 2026 shows that Biommm has entered a new cycle of sustainable growth. The structural advances of recent years, with investments to operationalize our manufacturing unit and establish long-term partnerships, generate consistent results and create a solid foundation for future expansion.

We maintain our mission to expand access to high-complexity therapies in Brazil, strengthening the national health system and reducing dependence on imports. This performance is based on ESG practices, with operations conducted under strict discipline and a focus on long-term value. We would like to thank all the employees for their excellence in execution, and the shareholders for the trust that made possible the achievement of this new and promising stage of Biommm.



## Financial performance



### Net revenue

In the first quarter of 2026 (1Q26), the Company recorded consolidated net revenue of R\$ 92.5 million, accounting for a growth of 134% (R\$ 39.6 million reported in the same period of 2025). The performance was driven by the solid execution of the Productive Development Partnerships (PDP), with emphasis on Wosulin<sup>®</sup>, which accounted for 74.8% of the total net revenue, followed by sales of Glargilin<sup>®</sup> in the private market (distributors and pharmacy chains), responsible for another 24.1% of the revenue.

Glargilin<sup>®</sup> had no sales through the Productive Development Partnership in 1Q26, as the Ministry of Health did not issue purchase orders while still working on defining the delivery schedule for the full year of 2026. The publication of this forecast occurred in May, including the confirmation of the delivery volume of Glargilin<sup>®</sup> to Fiocruz / Biomanguinhos, starting from 2Q26.

### Gross income and margin

The consolidated gross profit totaled R\$ 33.9 million in 1Q26, accounting for an increase of 363% (R\$ 7.3 million in the same period of 2025). The gross margin was driven by the gain in scale in deliveries and by the optimization of fixed production costs. This result highlights the Company's ability to convert the increase in sales volume into profitability, significantly surpassing the growth rate of billing.

### Operating expenses (SG&A)

Sales, general and administrative expenses, net of other operating revenues/expenses, totaled R\$ 22.8 million in 1Q26. The 13% increase over 1Q25 demonstrates the efficiency gain of Biommm's operational structure, since in the same period net revenue increased by 134%, highlighting the management team's focus on financial discipline and capturing synergies.


### Ebitda



**Biommm S.A.**

Individual and consolidated interim financial statements as of March 31, 2026

The consolidated EBITDA reached a positive level of R\$ 12.4 million in 1Q26, showing a significant improvement compared to the negative 10.7 million in the same period of 2025. This performance confirms the operational value generation trajectory after the historic positive annual EBITDA achieved in 2025. The performance is a direct result of operational leverage, characterized by the strong expansion of the gross margin that easily absorbed the variation in operating expenses during the period.



Statement of EBITDA (Consolidated in thousands of Reais)	03/31/2026	03/31/2025
Income (loss) for the year	9,692	(11,735)
Current income tax and social contribution	3,478	-
Deferred income tax and social contribution	(1,464)	(890)
Financial income (loss)	(695)	(211)
Depreciation and amortization	1,384	2,145
<b>EBITDA</b>	<b>12,395</b>	<b>(10,691)</b>

Financial income (loss)

The net financial income (loss) was positive by R\$ 695 thousand in the first quarter of 2026 (positive by R\$ 211 thousand in the same period of 2025). This performance is mainly due to the reduction of expenses with interest on loans, reflecting the Company’s liability optimization strategy. Furthermore, the result was positively impacted by foreign exchange gain during the period, which contributed to maintaining the net profitability of the quarter.

Net Income

The Company recorded net income of R\$ 9.7 million in 1Q26 (a loss of R\$ 11.7 million in the same period of the previous year). The performance consolidates the trajectory of profitability expansion started in 2025, and reflects the maturation of the Company’s biotechnological platform, reaffirming its ability to generate value robustly after the completion of the pre-operating phase.



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*
**Balance sheet**  
*(In thousands of reais)*

	Notes	Parent Company		Consolidated	
		03/31/2026	12/31/2025	03/31/2026	12/31/2025
<b>Assets</b>					
Current assets					
Cash and cash equivalents	4	20,605	21,946	20,615	22,304
Interest earning bank deposits	5	793	11,112	10,202	20,883
Accounts receivable	6	81,043	108,838	81,043	108,838
Inventories	7	183,046	97,272	183,046	97,272
Recoverable taxes	8	14,064	15,654	14,064	15,654
Advance to supplier	9	10,894	15,620	10,894	15,620
Other assets		1,476	441	1,738	488
<b>Total current assets</b>		<b>311,921</b>	<b>270,883</b>	<b>321,602</b>	<b>281,059</b>
<b>Non-current assets</b>					
Long-term assets					
Interest earning bank deposits	5	20,657	14,738	20,657	14,738
Judicial deposits		1,269	1,231	1,269	1,231
Accounts receivable - related parties	16	2,799	2,951	-	-
Deferred taxes	17	742	-	742	-
<b>Total long-term assets</b>		<b>25,467</b>	<b>18,920</b>	<b>22,668</b>	<b>15,969</b>
Investments	10	994	1,022	-	-
Property, plant and equipment	11	164,514	163,807	164,514	163,807
Intangible assets	12	63,780	62,448	64,668	63,395
<b>Total non-current assets</b>		<b>254,755</b>	<b>246,197</b>	<b>251,850</b>	<b>243,171</b>
<b>Total assets</b>		<b>566,676</b>	<b>517,080</b>	<b>573,452</b>	<b>524,230</b>

See the accompanying notes to the quarterly information (ITR).



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

## Balance sheet

(In thousands of reais)

	Notes	Parent Company		Consolidated	
		03/31/2026	12/31/2025	03/31/2026	12/31/2025
<b>Liabilities</b>					
Current liabilities					
Suppliers	13	111,548	66,571	111,548	66,571
Loans and financing	15	54,113	45,693	54,113	45,693
Taxes payable		2,209	2,195	2,209	2,195
Salaries and payroll charges		11,885	9,788	11,885	9,788
Securities payable	14	1,568	1,551	1,568	1,551
Other accounts payable		516	424	516	424
<b>Total current liabilities</b>		<b>181,839</b>	<b>126,222</b>	<b>181,839</b>	<b>126,222</b>
<b>Non-current liabilities</b>					
Securities payable	14	14,113	13,966	14,113	13,966
Loans and financing	15	35,787	50,911	35,787	50,911
Accounts payable - Related parties	16	6,766	7,133	13,698	14,441
Deferred taxes	17	-	722	-	722
Contingencies	18	3,147	3,036	3,147	3,036
Other accounts payable		1,666	1,582	1,510	1,424
<b>Total non-current liabilities</b>		<b>61,479</b>	<b>77,350</b>	<b>68,255</b>	<b>84,500</b>
<b>Shareholders' equity</b>	20				
Capital		957,654	957,501	957,654	957,501
Capital reserve		15,749	15,749	15,749	15,749
Accumulated losses		(650,637)	(660,329)	(650,637)	(660,329)
Accumulated translation adjustments		592	587	592	587
<b>Total shareholders' equity</b>		<b>323,358</b>	<b>313,508</b>	<b>323,358</b>	<b>313,508</b>
<b>Total liabilities and shareholders' equity</b>		<b>566,676</b>	<b>517,080</b>	<b>573,452</b>	<b>524,230</b>

See the accompanying notes to the quarterly information (ITR).



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*
**Statement of income for the year (DRE)**
*(In thousands of reais, except earnings/losses per share)*

	Notes	Parent Company		Consolidated	
		03/31/2026	03/31/2025	03/31/2026	03/31/2025
Net operating revenue	21	92,455	39,591	92,455	39,591
Costs of goods sold	22	(58,596)	(32,273)	(58,596)	(32,273)
<b>Gross income</b>		<b>33,859</b>	<b>7,318</b>	<b>33,859</b>	<b>7,318</b>
Operating revenues (expenses)					
Sales expenses	23	(9,474)	(7,230)	(9,485)	(7,230)
General and administrative expenses	23	(12,017)	(10,319)	(12,111)	(10,410)
Net reversals through impairment loss on accounts receivable	23	161	-	161	-
Other expenses and/or revenues	23	(1,413)	(2,514)	(1,413)	(2,514)
Equity in net income of subsidiaries	10	13	57	-	-
<b>Operating income (loss) before financial income (loss)</b>		<b>11,129</b>	<b>(12,688)</b>	<b>11,011</b>	<b>(12,836)</b>
<b>Financial income (loss)</b>					
Financial revenues	24	10,701	10,730	10,819	10,881
Financial expenses	24	(10,124)	(10,667)	(10,124)	(10,670)
<b>Net financial revenues (expenses)</b>		<b>577</b>	<b>63</b>	<b>695</b>	<b>211</b>
<b>Income (loss) before income taxes</b>		<b>11,706</b>	<b>(12,625)</b>	<b>11,706</b>	<b>(12,625)</b>
Income tax and social contribution - current	17	(3,478)	-	(3,478)	-
Deferred income tax and social contribution	17	1,464	890	1,464	890
<b>Income (loss) for the year</b>		<b>9,692</b>	<b>(11,735)</b>	<b>9,692</b>	<b>(11,735)</b>
<b>Earnings (loss) per share (in R\$)</b>					
Basic	25			0.07	(0.10)
Diluted	25			0.07	(0.10)

See the accompanying notes to the quarterly information (ITR).



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

## Statement of Comprehensive Income

*(In thousands of reais)*

	Parent Company		Consolidated	
	03/31/2026	03/31/2025	03/31/2026	03/31/2025
Income (loss) for the year	9,692	(11,735)	9,692	(11,735)
Other net comprehensive income not reclassified into income (loss) for the subsequent years:				
Translation adjustment of investee abroad	5	(57)	5	(57)
<b>Total comprehensive income</b>	<b>9,697</b>	<b>(11,792)</b>	<b>9,697</b>	<b>(11,792)</b>

See the accompanying notes to the quarterly information (ITR).



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*
**Statement of changes in shareholders' equity**
*(In thousands of reais)*

	Capital	Capital reserves	Accumulated losses	Equity valuation adjustment	Total
<b>Balances at January 1, 2025</b>	<b>900,000</b>	<b>15,749</b>	<b>(653,642)</b>	<b>677</b>	<b>262,784</b>
Paid-up capital	1	-	-	-	1
Loss for the year	-	-	(11,735)	-	(11,735)
Translation adjustment of investee abroad	-	-	-	(57)	(57)
<b>Balances at March 31, 2025</b>	<b>900,001</b>	<b>15,749</b>	<b>(665,377)</b>	<b>620</b>	<b>250,993</b>
<b>Balances at January 1, 2026</b>	<b>957,501</b>	<b>15,749</b>	<b>(660,329)</b>	<b>587</b>	<b>313,508</b>
Paid-up capital	153	-	-	-	153.00
Income for the year	-	-	9,692	-	9,692
Translation adjustment of investee abroad	-	-	-	5	5
<b>Balances at March 31, 2026</b>	<b>957,654</b>	<b>15,749</b>	<b>(650,637)</b>	<b>592</b>	<b>323,358</b>

See the accompanying notes to the quarterly information (ITR).



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

## Statement of cash flows

*(In thousands of reais)*

	Notes	Parent Company		Consolidated	
		03/31/2026	03/31/2025	03/31/2026	03/31/2025
<b>Cash flow from operating activities</b>					
Income (loss) for the period		9,692	(11,735)	9,692	(11,735)
Depreciation/amortization	11   12	1,373	2,146	1,384	2,145
Equity in net income of subsidiaries	10	(13)	(57)	-	-
Deferred income tax and social contribution	17	2,014	(889)	2,014	(889)
Accrued interest	15	2,137	2,745	2,137	2,745
Revenues from interest earning bank deposits and other financial revenues		(1,423)	(2,612)	(1,584)	(2,762)
Unrealized exchange-rate changes, net		(685)	858	(687)	38
Formation (reversal) of provision for contingencies	18	111	1,100	111	1,100
Provision (reversals) for losses	6 7	387	(497)	387	(497)
Long-term incentive	19	172	633	172	633
		<b>13,765</b>	<b>(8,308)</b>	<b>13,626</b>	<b>(9,222)</b>
Changes in operating assets and liabilities:					
(Increase) decrease in accounts receivable		27,956	(5,816)	27,956	(5,816)
(Increase) decrease in inventories		(85,377)	(9,567)	(85,377)	(9,567)
(Increase) decrease in other assets		7,113	3,610	6,940	3,355
(Decrease) in suppliers and securities payable		46,749	4,249	46,749	4,249
Increase (decrease) in salaries and charges		2,097	(1,712)	2,097	(1,712)
Increase (decrease) in other liabilities		(6,601)	(1,876)	(6,641)	(1,839)
		<b>5,703</b>	<b>(19,420)</b>	<b>5,350</b>	<b>(20,553)</b>
<b>Cash generated by (used in) operating activities</b>					
Payment of interest on loans		(1,417)	(1,999)	(1,417)	(1,999)
Payments of interest on leases		(152)	(22)	(152)	(22)
		<b>4,134</b>	<b>(21,441)</b>	<b>3,781</b>	<b>(22,574)</b>
<b>Net cash (invested in) from operating activities</b>					
Cash flow from investment activities					
Acquisition of property, plant and equipment and intangible assets	11   12	(4,453)	(2,740)	(4,453)	(2,739)
Interest earning bank deposits made		(142,926)	(72,446)	(159,335)	(71,091)
Interest earning bank deposits redeemed		149,022	89,925	165,431	89,471
		<b>1,643</b>	<b>14,739</b>	<b>1,643</b>	<b>15,641</b>
<b>Net cash (invested in) generated by investment activities</b>					
Cash flow from financing activities					
Payment of loans and financing		(6,755)	(5,921)	(6,755)	(5,921)
Payment of leases		(516)	(117)	(516)	(117)
Capital increase		153	1	153	1
		<b>(7,118)</b>	<b>(6,037)</b>	<b>(7,118)</b>	<b>(6,037)</b>
<b>Net cash generated (used in) in financing activities</b>					
<b>Decrease in cash and cash equivalents</b>					
Cash and cash equivalents at the beginning of the year		21,946	76,742	22,304	77,620
Exchange-rate change on cash		-	(508)	5	(508)
Cash and cash equivalents at the end of the year		20,605	63,495	20,615	64,142
		<b>(1,341)</b>	<b>(12,739)</b>	<b>(1,694)</b>	<b>(12,970)</b>
<b>Decrease in cash and cash equivalents</b>					

See the accompanying notes to the quarterly information (ITR).



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

## Statement of added value (SAV)

*(In thousands of reais)*

	Notes	Parent Company		Consolidated	
		03/31/2026	03/31/2025	03/31/2026	03/31/2025
<b>Revenues</b>					
Revenue from contract with customer		108,636	41,569	108,636	41,569
Revenue from construction of own assets		2,381	1,411	2,381	1,411
Allowance for doubtful accounts - Reversal / (Formation)		161	(24)	161	(24)
		<b>111,178</b>	<b>42,956</b>	<b>111,178</b>	<b>42,956</b>
<b>Costs</b>					
Costs of resale of goods	22	(58,095)	(32,273)	(58,095)	(32,273)
Cost related to Construction in progress		(2,381)	(1,411)	(2,381)	(1,411)
Materials, energy, outsourced services and other		(8,411)	(5,179)	(8,505)	(5,270)
Loss and recovery of asset values	7	(598)	(473)	(598)	(473)
Inputs acquired from third parties		(69,485)	(39,336)	(69,579)	(39,427)
<b>Gross added value</b>		<b>41,693</b>	<b>3,620</b>	<b>41,599</b>	<b>3,529</b>
Depreciation and amortization	11   12	(1,373)	(2,144)	(1,384)	(2,144)
<b>Net added value produced by the Company</b>		<b>40,320</b>	<b>1,476</b>	<b>40,215</b>	<b>1,385</b>
Equity in net income of subsidiaries	10	13	57	-	-
Financial revenues	24	10,701	10,730	10,819	10,881
Other		6	(1,206)	6	(1,206)
Added value received as transfer		10,720	9,581	10,825	9,675
<b>Total net added value payable</b>		<b>51,040</b>	<b>11,057</b>	<b>51,040</b>	<b>11,060</b>
Distribution of added value:		51,040	11,057	51,040	11,060
<b>Personnel</b>		<b>8,683</b>	<b>7,959</b>	<b>8,683</b>	<b>7,959</b>
Direct remuneration		6,739	6,494	6,739	6,494
Benefits		1,310	1,112	1,310	1,112
FGTS		388	353	388	353
Other		246	-	246	-
<b>Taxes, rates and contributions</b>		<b>20,758</b>	<b>3,475</b>	<b>20,758</b>	<b>3,475</b>
Federal		4,449	1,273	4,449	1,273
State		16,112	1,946	16,112	1,946
Municipal		197	256	197	256
<b>Third-party capital remuneration:</b>		<b>11,907</b>	<b>11,357</b>	<b>11,907</b>	<b>11,360</b>
Interest		9,508	11,222	9,508	11,225
Rents		1,089	550	1,089	550
Other		1,310	(415)	1,310	(415)
<b>Remuneration of own capital</b>		<b>9,692</b>	<b>(11,735)</b>	<b>9,692</b>	<b>(11,735)</b>
Income/(loss) for the year		9,692	(11,735)	9,692	(11,735)

See the accompanying notes to the quarterly information (ITR).



**Biommm S.A.**

Individual and consolidated interim financial statements as of March 31, 2026

## Notes to the quarterly information - ITR

(In thousands of reais, unless otherwise indicated)

### 1. Operations

#### a) General information

Biommm S.A. (“Biommm” or “Company”), founded in 2001 through the partial spin-off of Biobrás S.A., is a publicly-held corporation headquartered at Avenida Regent, 705, Nova Lima, Minas Gerais. The Company is listed on the Bovespa Mais segment of B3 S.A. under the ticker BIOM3.

The Company is a pioneer in the biotechnology sector in Brazil, holding strategic patents (USA, Canada, Europe, Brazil, and India) for the production of insulins through recombinant DNA technology. Its business purpose includes the development, manufacturing, and commercialization of biopharmaceuticals intended for the treatment of chronic diseases, focusing on diabetes, oncology, ophthalmology, bone diseases, and anticoagulants.

#### b) Manufacturing Unit and Certifications

The Company operates its industrial unit in Nova Lima (MG), a biotechnological complex dedicated to the production of recombinant therapeutic proteins. The plant operates with Good Manufacturing Practices (GMP) certification issued by ANVISA, being fully authorized as a manufacturing site for the biological product Glargilin®.

#### c) Business Model and Strategic Partnerships

Currently, the Company maintains exclusive partnerships for the Brazilian market with global companies, including:

- (a) Asia: Gan&Lee, Bio-Thera, CanSinoBIO, Huisheng Biopharmaceutical, Kexing Biopharm (China); Wockhardt, Enzene, Lupin, Biocon (India); and Celltrion Healthcare (South Korea).
- (b) Europe: Chemi (Italy) and Bioeq (Switzerland).

#### d) Partnerships for Productive Development (PDP)

The Company is an active agent in the Productive Development Partnerships (PDP) program of the Ministry of Health:

- **Human Insulin (Regular and NPH):** Established between Biommm, Funed, and Wockhardt, this PDP constitutes a pillar for the self-sufficiency of the Health Economic-Industrial Complex. Under the cooperation model, Biommm acts as the private technology arm, responsible for supply, future national manufacturing, and technical support, while Funed coordinates the technology absorption for the public entity and Wockhardt provides the licensed technology.
- **Insulin Glargine:** This is the Productive Development Partnership (PDP) between Biommm, Bio-Manguinhos/Fiocruz, and Gan & Lee. Biommm already carries out the national production of this biopharmaceutical at its industrial plant, completing the packaging and quality control stages. The partnership operates through the gradual transfer of knowledge from Gan & Lee to Biommm and Fiocruz.

### 2. Basis for preparation and presentation of quarterly information (ITR)



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

**a. Statement of conformity**

The individual and consolidated quarterly information was prepared and is presented in accordance with to the Technical Pronouncement CPC 21 (R1) - Interim Financial Reporting and the International Standard IAS 34 – Interim Financial Reporting issued by the International Accounting Standards Board - IASB, as well as for the presentation of this information in a manner consistent with the standards issued by the Brazilian Exchange and Securities Commission (CVM), applicable to the preparation of the Quarterly Information.

The statement of added value, although not required by the IFRS, is mandatory for publicly-held companies in Brazil, and is included as an integral part of this financial statement with the appropriate breakdown of the components, in accordance with the rules of CVM Resolution 199.2024. The purpose of this statement is to show the wealth created by the Company and its distribution during a certain period and adjusted as supplementary information to the individual and consolidated quarterly information.

Furthermore, the Company considered Technical Guideline OCPC 07 in the preparation of its quarterly information (ITR). Accordingly, material facts of the quarterly information is being evidenced and corresponds to the information used by Management when administrating.

**b. Basis of preparation**

The material accounting policies and use of estimates and judgments applied in this Quarterly Information (ITR) are consistent with the policies and judgments described in Notes 3 and 4, respectively, of the Company's annual financial statements for the year ended December 31, 2025, filed with the Brazilian Securities and Exchange Commission (CVM). These policies and judgments were adopted and applied uniformly in all periods presented. The quarterly information for the period ended March 31, 2026 should be read together with Company's financial statements for the year ended December 31, 2025.

These financial statements were approved by the Executive Board on May 15, 2026.

**c. Functional and presentation currency**

The Company's functional currency and presentation currency of individual and consolidated financial statements is the Real ("BRL" or "R\$"). The financial statements are presented in thousands of reais, unless otherwise indicated.

The results and financial position of foreign subsidiaries have been converted into the presentation currency, which is the Real (R\$), using the following procedures: (a) assets and liabilities were translated by using the closing exchange-rate on the date of the respective balance sheet; (b) revenues and expenses were translated at the exchange rates in force on the dates the transactions took place; and (c) all resulting exchange-rate changes were recognized in other comprehensive income.

**d. Notes presented in the annual financial statements that are not presented in this interim financial information**

The Company opened the notes considered relevant in the context of the "Basic Conceptual Pronouncement - Conceptual Framework for the Preparation and Presentation of Financial Statements". All information whose its



**Biommm S.A.**

Individual and consolidated interim financial statements as of March 31, 2026

omission or misstatement could influence the economic decisions of users were duly disclosed in this Quarterly Information (ITR) which should be read together with the financial statements as of December 31, 2025.

We indicate below the exact location of the notes whose information has not been repeated in this quarterly information, either due to redundancy or relevance:

1. Note 3 - Use of estimates and judgments;
2. Note 4 – Material accounting policies;
3. Note 5 – New standards and interpretations;
4. Note 18 - Private pension plan;
5. Note 19 – Insurance coverage;

In the period ended March 31, 2026, there were no changes in the nature and conditions of notes above in relation to that described in notes of Company’s Quarterly Information (ITR) for the year ended December 31, 2025.

**3. Consolidation**

Subsidiaries consolidated on March 31, 2026 are:

Companies	% interest in capital		Location of the headquarters
	2026	2025	
Biommm International Inc.	100	100	British Virgin Islands
Biommm Middle East Inc. (*)	100	100	British Virgin Islands

<sup>1</sup> Presented interest represents the percentage indirectly held by the investor company in the capital of Subsidiary.

Biommm International Inc. was incorporated on April 29, 2003, with its head office in Road Town, Tortola, capital of the British Virgin Islands. Biommm subscribed to all of the shares of Biommm International Inc., however, these shares, corresponding to US\$ 50 thousand, were not fully paid up, as permitted by the legislation of that country.

Biommm International Inc.’s wholly-owned subsidiary, Biommm Middle East Inc., is also based in Road Town, British Virgin Islands. Biommm International Inc. subscribed to all the shares, corresponding to US\$ 50 thousand of the new companies, as permitted by the legislation of that country. The company was set up to facilitate the negotiation of international contracts. Biommm Middle East Inc. is directly linked to the Saudi Arabian project.

**4. Cash and cash equivalents**

	Parent Company		Consolidated	
	03/31/2026	12/31/2025	03/31/2026	12/31/2025
Cash and banks in domestic currency	3,584	6,828	3,584	6,828



## Biommm S.A.

Individual and consolidated interim financial statements as of March 31, 2026

Cash and banks in foreign currencies	26	25	36	36
Interest earning bank deposits	1,255	3,203	1,255	3,203
Interest earning bank deposits - Time Deposit USD <sup>1</sup>	15,740	11,890	15,740	12,237
	<b>20,605</b>	<b>21,946</b>	<b>20,615</b>	<b>22,304</b>

Cash and cash equivalents comprise cash on hand, bank deposit certificates, and interest earning bank deposits with insignificant risk of change in value. Investments in domestic currency have daily liquidity and present a weighted average profitability of 14.0% p.a., corresponding to 95.3% of the CDI (13.3% p.a., corresponding to 93.1% of the CDI as of December 31, 2025).

<sup>1</sup> Investments in foreign currency have a return applied to simple interest, with a weighted average of 4.0% p.a. with no index.

## 5. Interest earning bank deposits

	Parent Company		Consolidated	
	03/31/2026	12/31/2025	03/31/2026	12/31/2025
Short-term CDB	793	11,112	793	11,113
Long-term CDB	20,657	14,738	20,657	14,738
Interest earning bank deposits - Time Deposit USD	-	-	9,409	9,770
	<b>21,450</b>	<b>25,850</b>	<b>30,859</b>	<b>35,621</b>
Current	793	11,112	10,202	20,883
Non-current	20,657	14,738	20,657	14,738

On March 31, 2026, the Company invested the funds in the form of bank deposit certificates, issued by first-tier banks with low credit risks. These investments had a weighted average return over the last 12 months of 14.40% p.a., with 97.9% of the CDI as of March 31, 2026 (14.0% p.a., with 98.1% of the CDI as of December 31, 2025) and investments in foreign currency have a return applied to simple interest, with a weighted average of 4.96% p.a. with no index.

The amount of short-term interest earning bank deposits (R\$ 9,409) and long-term interest earning bank deposits (R\$ 20,657) is encumbered by fiduciary assignments and collateral (short-term interest earning bank deposits (R\$ 9,770) and long-term interest earning bank deposits (R\$ 14,738), as of December 31, 2025), as detailed below:

Contract Law 4131 (Banco ABC): Guaranteed by the investment in Time Deposits (R\$ 9,409) and assignment of fixed income securities (R\$ 9,770 as of December 31, 2025).

Financing (linked CDBs):

- (i) FINEP: R\$ 15,289 (R\$ 9,370 as of December 31, 2025),
- (ii) BNDES: R\$ 1,287 (R\$ 1,287 as of December 31, 2025),
- (iii) BDMG: R\$ 4,081 (R\$ 4,081 as of December 31, 2025).

## 6. Accounts receivable



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
Domestic clients	81,517	109,473
Provision for estimated loss	(474)	(635)
	<b>81,043</b>	<b>108,838</b>

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
Domestic clients	81,517	109,473
Provision for estimated loss	(474)	(635)
	<b>81,043</b>	<b>108,838</b>

The balances per maturity of accounts receivable are as follows:

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
Falling due	70,418	108,326
Overdue	11,099	1,147
	<b>81,517</b>	<b>109,473</b>

Overdue (days):		
01-30	10,051	-
31-60	-	749
61-180	651	-
>181	398	398

Changes in estimated losses are as follows:

	Parent Company and Consolidated	
	03/31/2026	03/31/2025
Opening balance	(635)	(199)
(Additions) reversal to income (loss)	161	(24)
<b>Closing balance</b>	<b>(474)</b>	<b>(223)</b>



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

## 7. Inventories

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
Good for resale	19,613	5,583
Goods for sale	27,574	12,154
Inventories in transit (i)	76,516	33,231
Inventories held by third parties	-	14,352
Work in process	16,342	10,421
Raw material	39,816	21,325
Other inventories	3,185	2,140
Provision for impairment	-	(1,934)
	<b>183,046</b>	<b>97,272</b>

(i) Inventories in transit: resale merchandise for commercialization and imported inputs for local production.

The inventories balance on March 31, 2026, totals R\$ 183,046, covering goods for resale, work in progress, raw materials, and inputs for local production. This storage structure aims to meet the delivery schedules planned for the upcoming periods related to already signed contracts and the private market, maintaining safety levels consistent with the contracted and estimated demand.

Management continuously monitors the recoverability of all its inventories, maintaining provision for impairment that covers risks of expiration, quality, and obsolescence. On March 31, 2026, the provision totaled R\$ 2,482, an amount considered sufficient to cover potential losses. The realization tests are based on the comparison between the average cost of purchase/production and the net realizable value. The changes in the provision for losses on goods for trading are outlined below:

	Parent Company and Consolidated	
	03/31/2026	03/31/2025
Opening balance	(1,934)	(488)
Additions to income (loss)	(594)	(2,052)
Reversals in income (loss)	46	1,569
<b>Closing balance</b>	<b>(2,482)</b>	<b>(971)</b>

## 8. Recoverable taxes

Breakdown of balance of taxes recoverable is as follows:

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
PIS and COFINS	6,452	5,418
Withholding income tax on interest earning bank deposit	3,698	3,698
Income tax and social contribution	2,614	5,829
Excise Tax	1,197	634
Other taxes	103	75



**Biommm S.A.**

Individual and consolidated interim financial statements as of March 31, 2026

Total recoverable taxes	14,064	15,654
-------------------------	--------	--------

The company estimates that all of these credits will be realized through offsetting with its own taxes in the course of operations within 12 months.

**9. Advance to Supplier**

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
Advances to suppliers in domestic currency	5,756	1,250
Advance to supplier in foreign currency	5,138	14,370
	<b>10,894</b>	<b>15,620</b>

Advances to suppliers in foreign currency correspond substantially to the import of goods for sale.

**10. Investments**

**a) Breakdown**

	Interest in capital	Shareholders' equity / (unsecured liability)		Investments		Equity in net income of subsidiaries	
		03/31/2026	12/31/2025	03/31/2026	12/31/2025	03/31/2026	03/31/2025
Direct subsidiary:							
Biommm International Inc.	100%	-	-	994	1,022	19	60
Indirect subsidiaries:							
Biommm Middle East Inc.	100%	(155)	(158)	-	-	(6)	(3)
Jointly-controlled subsidiary:							
Gabass Global	15%	-	-	-	-	-	-
		<b>(155)</b>	<b>(158)</b>	<b>994</b>	<b>1,022</b>	<b>13</b>	<b>57</b>

In 2016, the company Gabass Global was impaired at R\$ 4,110, in addition to the provision for the accumulated translation adjustment on this investment of R\$ 2,260. The provision was held in the period ended March 31, 2026.



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*
**b) Changes**

Changes in investments are as follows:

	03/31/2026	12/31/2025
Opening balance	1,022	916
Equity in net income of subsidiaries	13	202
Transfer - unsecured liability	(3)	(6)
Accumulated translation adjustment	5	(90)
Investments vs. Omitted Liabilities	(43)	-
<b>Closing balance</b>	<b>994</b>	<b>1,022</b>

**c) Ownership interests in Investees**

The total balances of the equity and profit and loss accounts of directly and indirectly controlled companies and jointly-controlled subsidiaries, considered in the consolidated quarterly information (ITR), can be summarized as follows:

	Direct		Indirect	
	Biommm International		Biommm Middle East	
	03/31/2026	12/31/2025	03/31/2026	12/31/2025
<b>Balance sheet</b>				
Current assets	9,682	10,176	-	-
Non-current assets	7,809	8,238	-	-
Current liabilities	2,790	2,941	-	-
Non-current liabilities	13,707	14,451	155	158
	03/31/2026	03/31/2025	03/31/2026	03/31/2025
<b>Income (loss)</b>	<b>19</b>	<b>60</b>	<b>(6)</b>	<b>(3)</b>



**Biommm S.A.**

Individual and consolidated interim financial statements as of March 31, 2026

## 11. Property, plant and equipment

	Average depreciation rate	Parent Company and Consolidated			
		03/31/2026		12/31/2025	
		Cost	Accumulated depreciation	Net	Net
Land		13,851	0	13,851	13,851
Buildings	1.72%	60,781	(4,553)	56,228	56,357
Facilities	9.77%	16,059	(5,513)	10,546	10,702
Machinery and equipment	4.80%	85,052	(11,981)	73,071	73,976
Data processing equipment	20%	4,295	(1,998)	2,297	2,444
Construction in progress	-	6,220	-	6,220	4,136
Rights-of-use	12.50%	967	(488)	479	568
Other	14.17%	3,110	(1,288)	1,822	1,773
		<b>190,335</b>	<b>(25,821)</b>	<b>164,514</b>	<b>163,807</b>

Changes in property, plant and equipment are as follows:

	Parent Company and Consolidated					
	12/31/2025	Additions	Depreciation	Transfer	Write-offs	03/31/2026
Land	13,851	-	-	-	-	13,851
Buildings	56,357	-	(129)	-	-	56,228
Facilities	10,702	-	(156)	-	-	10,546
Machinery and equipment	73,976	128	(1,033)	-	-	73,071
Data processing equipment	2,444	31	(178)	-	-	2,297
Construction in progress	4,136	2,381	-	(297)	-	6,220
Rights-of-use	568	17	(106)	-	-	479
Other	1,773	101	(52)	-	-	1,822
	<b>163,807</b>	<b>2,658</b>	<b>(1,654)</b>	<b>(297)</b>	<b>-</b>	<b>164,514</b>



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

	Parent Company and Consolidated					
	12/31/2024	Additions	Depreciation	Transfer	Write-offs	03/31/2025
Land	13,851	-	-	-	-	13,851
Buildings	57,326	-	(241)	-	-	57,085
Facilities	11,502	-	(353)	-	-	11,149
Machinery and equipment	76,787	7	(946)	-	-	75,848
Data processing equipment	1,920	212	(145)	-	-	1,987
Construction in progress	4,327	1,411	-	-	-	5,738
Rights-of-use	459	0	(100)	-	-	359
Other	1,473	19	(55)	-	-	1,437
	<b>167,645</b>	<b>1,649</b>	<b>(1,840)</b>	<b>-</b>	<b>-</b>	<b>167,454</b>

The balance of construction in progress is substantially composed of investments aimed at expanding productive capacity, modernization of assets, and adaptation of technical infrastructure. As of March 31, 2026, the amount refers to:

- (i) acquisition of machinery and equipment aimed at the development of new product lines;
- (ii) improvements and upgrades to machinery and existing facilities; and
- (iii) property, plant and equipment in the process of assembly, installation, and commissioning. Such items will be transferred to the property, plant and equipment in operation accounts and their depreciation will begin from the moment they are in the intended conditions of use by management.

The Company's rights of use are linked to physical structure rental contracts, totaling a net amount of R\$ 479 (R\$ 568 as of December 31, 2025).

On March 31, 2026, property, plant and equipment totaling R\$ 164,514 comprise collateral for bank loans (R\$ 163,807 as of December 31, 2025).

## 12. Intangible assets

	Average rate of amortization	Parent Company			
		03/31/2026		12/31/2025	
		Cost	Accumulated amortization	Net	Net
Tests and prototypes (i)	5%	27,103	(339)	26,764	27,103
Software	9.60%	4,609	(1,755)	2,854	2,940
Trademarks and licenses (ii)	17.71%	14,254	(3,614)	10,640	10,878
Advance to intangible assets (iii)	-	4,275	-	4,275	4,388
Intangible assets in progress (iii)	-	19,247	-	19,247	17,139
		<b>69,488</b>	<b>(5,708)</b>	<b>63,780</b>	<b>62,448</b>

Consolidated



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

	Average rate of amortization	03/31/2026		12/31/2025	
		Cost	Accumulated amortization	Net	Net
Tests and prototypes (i)	5%	28,002	(350)	27,652	28,050
Software	9.60%	4,609	(1,755)	2,854	2,940
Trademarks and licenses (ii)	17.71%	14,254	(3,614)	10,640	10,878
Advance to intangible assets (iii)	-	4,275	-	4,275	4,388
Intangible assets in progress (iii)	-	19,247	-	19,247	17,139
		<b>70,387</b>	<b>(5,719)</b>	<b>64,668</b>	<b>63,395</b>

The balance of Intangible assets is comprised of the following elements:

- (i) Tests and prototypes: they include investments in technology and processes carried out through Contract Manufacturing Organization (CMO) and internal development, whose clinical and preclinical tests have been successfully completed. The completion of these stages consolidated the Company's biotechnological expertise, making it fully capable of the own production of Glargine insulin and the industrial scaling of its biosimilar portfolio at the manufacturing facility in Nova Lima (MG). Amortization began in January 2026, based on the readiness for full-capacity use of the industrial plant and an estimated useful life of 20 years;
- (ii) Trademarks and licenses: include the registration of brands in the Biommm portfolio and the acquisition of exclusive rights to sell products in the Brazilian market; and
- (iii) Intangible assets in progress: refers mainly to investments in the deployment project of the SAP S/4HANA management system, in addition to capitalized expenses related to obtaining regulatory approvals and the development of new products that meet the criteria of technical feasibility. These assets will be transferred to the final accounts and their Amortization will begin as soon as the systems become operational or the products start to generate economic benefits for the Company.

Changes in intangible assets are as follows:

	Parent Company						03/31/2026
	12/31/2025	Additions	Amortization	Transfer	Write-offs	Foreign exchange rate	
Tests and prototypes	27,103	-	(339)	-	-	-	26,764
Software	2,940	1	(87)	-	-	-	2,854
Trademarks and licenses	10,878	-	(238)	-	-	-	10,640
Advance to intangible assets	4,388	-	-	-	-	(113)	4,275
Intangible assets in progress	17,139	1,811	-	297	-	-	19,247
	<b>62,448</b>	<b>1,812</b>	<b>(664)</b>	<b>297</b>	<b>-</b>	<b>(113)</b>	<b>63,780</b>

	Consolidated						03/31/2026
	12/31/2025	Additions	Amortization	Transfer	Write-offs	Exchange-rate change	



**Biom S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

Tests and prototypes	28,050	-	(350)	-	-	(48)	27,652
Software	2,940	1	(87)	-	-	-	2,854
Trademarks and licenses	10,878	-	(238)	-	-	-	10,640
Advance to intangible assets	4,388	-	-	-	-	(113)	4,275
Intangible assets in progress	17,139	1,811	-	297	-	-	19,247
	<b>63,395</b>	<b>1,812</b>	<b>(675)</b>	<b>297</b>	<b>-</b>	<b>(161)</b>	<b>64,668</b>

**Parent Company**

	12/31/2024	Additions	Amortization	Transfer	Write-offs	Exchange-rate change	03/31/2025
Tests and prototypes	27,103	-	-	-	-	-	27,103
Software	3,305	-	(96)	-	-	-	3,209
Trademarks and licenses	8,032	-	(209)	-	-	-	7,823
Advance to intangible assets	2,635	-	-	-	(180)	-	2,455
Intangible assets in progress	3,578	1,091	-	-	-	-	4,669
	<b>44,653</b>	<b>1,091</b>	<b>(305)</b>	<b>-</b>	<b>(180)</b>	<b>-</b>	<b>45,259</b>

**Consolidated**

	12/31/2024	Additions	Amortization	Transfer	Write-offs	Exchange-rate change	03/31/2025
Tests and prototypes	28,169	-	-	-	-	(77)	28,092
Software	3,305	-	(96)	-	-	-	3,209
Trademarks and licenses	8,032	-	(209)	-	-	-	7,823
Advance to intangible assets	2,635	-	-	-	-	(180)	2,455
Intangible assets in progress	3,578	1,091	-	-	-	-	4,669
	<b>45,719</b>	<b>1,091</b>	<b>(305)</b>	<b>-</b>	<b>-</b>	<b>(257)</b>	<b>46,248</b>

**13. Suppliers**

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
Domestic suppliers	20,395	14,984
Foreign suppliers	91,153	51,587
	<b>111,548</b>	<b>66,571</b>



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

## 14. Securities payable

	Parent Company and Consolidated	
	03/31/2026	12/31/2025
Current	1,568	1,551
Non-current	14,113	13,966
	<b>15,681</b>	<b>15,517</b>

The amount of securities payable refers to the acquisition, in October 2016, of three plots of land located in the city of Jaboatão dos Guararapes (PE) and the property and acquisition rights to the stretch of a street located between these plots, in addition to the personal properties, utilities, and buildings incorporated into the Company's assets.

The balance payable is adjusted by the IPC-FIPE on an annual basis. The securities will be paid in 12 annual installments, the last of which will be due in 2035.

## 15. Loans and financing

Financial institution	Modality	Funding date	Final maturity date	Amount raised	Annual interest	03/31/2026	12/31/2025
BNDES	Long-term loan	01/23/2014	2027	73,557	TLP + 3.39%	20,616	23,806
BDMG - FINEM	Long-term loan	09/23/2016	2027	26,103	TLP + 4.05%	7,545	8,713
BDMG - FAPEMIG	Long-term loan	01/23/2014	2027	30,000	5.32%	7,608	8,811
FINEP	Long-term loan	03/14/2014	2027	54,129	TJLP	41,847	42,671
ABC	Short-term financing – US\$	05/14/2025	2026	12,505	7.60%	12,650	13,026
Funding costs						(366)	(423)
				<b>196,294</b>		<b>89,900</b>	<b>96,604</b>
Loans – current						54,113	45,693
Loans - non-current						35,787	50,911
						<b>89,900</b>	<b>96,604</b>

### Changes in loans

	03/31/2026	03/31/2025
Opening balance	96,604	121,383
Amortization of principal	(6,755)	(5,921)
Provisioned charges	2,080	2,687
Amortization of charges	(1,417)	(1,999)
Amortization of borrowing costs	57	58



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

Exchange-rate change	(669)	(1,074)
	<b>89,900</b>	<b>115,134</b>

Amounts recorded as non-current liabilities at March 31, 2026 mature in 2027. In addition to the collateral securities and personal guarantees previously reported (Note 5 - Interest earning bank deposits and Note 11 - Property, plant, and equipment), credit operations are guaranteed by receivables.

**Covenants**

The Company has two long-term financing agreements (BNDES and BDMG FINEM) that require the maintenance of certain restrictive financial covenants, measured annually. As of December 31, 2025, the Company did not meet the contractually provided for Net Debt/EBITDA ratio. Considering that the calculation of such indicators is strictly annual, there was no new measurement of covenants for the period ended March 31, 2026. The understanding remains unchanged that the non-achievement observed in the prior year does not constitute a breach of covenants, since, under the contractual terms, any non-compliance only constitutes an event of default after formal notification by the creditor and the applicable cure period has elapsed. Up to the date of authorization for the issuance of these interim financial statements, the Company has not been notified by said creditors, and no cure period has been initiated. Thus, as of this date, there is no event that characterizes early maturity, nor does the creditor have an unconditional right to demand immediate settlement, in accordance with the requirements of CPC 26 (IAS 1). Thus, the balances of the financing with BNDES and BDMG remain classified under non-current liabilities, in accordance with their respective amortization schedules.

**16. Related parties**

**a) The balances arising from transactions between related parties with undetermined maturities are as follows:**

	Parent Company	
	03/31/2026	12/31/2025
<b>Non-current assets</b>		
Accounts receivable - Related parties (i)	2,799	2,951
<b>Non-current liabilities</b>		
Accounts payable - Related parties (ii)	6,766	7,133
	03/31/2026	03/31/2025
<b>Income (loss)</b>		
Exchange-rate change (iv)	215	343

	Consolidated	
	03/31/2026	12/31/2025
<b>Non-current liabilities</b>		
Related party suppliers	71	-
Accounts payable – related parties (iii)	13,698	14,441
	03/31/2026	03/31/2025
<b>Income (loss)</b>		



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

Exchange-rate change (iv) 743 1,182

- (i) This refers to the balance receivable from its direct subsidiary, Biommm International, relating to royalties on the rights to insulin production technology. This balance bears no interest, is held in U.S. dollars, and has no provision for losses.
- (ii) The balance payable to Biommm International refers to the loan signed between the parties. This balance does not bear interest and is held in U.S. dollars.
- (iii) It refers to the balance received by Biommm International on the technology transfer contract with Gabas Global, which is expected to be settled upon completion of the technology transfer stages.
- (iv) Exchange rate effect of outstanding balances payable and receivable with related parties recognized in the Company’s financial income (loss).

**b) Remuneration of key management personnel**

Key management personnel includes board members and directors. The remuneration paid to key management personnel is as follows:

	Parent Company and Consolidated	
	03/31/2026	03/31/2025
Salaries and other short-term employee benefits	3,071	2,255
Share-based payment plan	172	633
Other long-term benefits	35	10
	<b>3,278</b>	<b>2,898</b>

Short-term benefits for employees and directors include fees and social charges for directors and the strategic committee, health care and other non-monetary benefits, as well as profit sharing for directors upon meeting the targets approved by the Board of Directors.

Long-term benefits include the directors’ private pension plan.

**17. Income taxes - Income tax and social contribution**

Income tax and social contribution are recorded based on recognized revenue, costs and expenses incurred under the accrual method. As of March 31, 2026, the Company recorded tax losses and a negative social contribution basis in the total amount of R\$ 666,261 (December 31, 2025 – R\$ 670,731). Said balance comprises tax losses generated in previous years and accumulated for future offsetting, with no accounting record of deferred tax assets on the accumulated loss basis due to the absence of a history of taxable income of the Company.

**a) Deferred income tax and social contribution assets and liabilities**

Parent Company and Consolidated	
03/31/2026	12/31/2025



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

Provision for statutory bonus and CLT	1,474	-
Provision for inventory loss	591	-
Provision for estimated credit loss	113	-
Provision for contingencies	749	-
Provision for suppliers (accrual)	534	-
ILP	342	-
Exchange-rate change	-	507
<b>Total deferred income tax and social contribution in assets</b>	<b>3,803</b>	<b>507</b>
Exchange-rate change	(862)	-
Accounting depreciation	(2,199)	(1,229)
<b>Total deferred income tax and social contribution liabilities</b>	<b>(3,061)</b>	<b>(1,229)</b>
<b>Total deferred income tax and social contribution, net</b>	<b>742</b>	<b>(722)</b>
Non-current assets	742	-
Non-current liabilities	-	(722)

Changes in deferred tax are as follows:

	Parent Company and Consolidated								
	Exchange-rate change	Accounting depreciation	PROFIT SHARING	Inventory loss	Provision		Suppliers	ILP	Total
Deferred tax assets and liabilities:					PCLD	Contingency			
December 31, 2024	(262)	(721)	-	-	-	-	-	-	(983)
Credited (debited) to the statement of income	711	(450)	-	-	-	-	-	-	261
December 31, 2025	<b>449</b>	<b>(1,171)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(722)</b>
Credited (debited) to the statement of income	(1,311)	(1,028)	1,474	591	113	749	535	342	1,464
March 31, 2026	<b>(862)</b>	<b>(2,199)</b>	<b>1,474</b>	<b>591</b>	<b>113</b>	<b>749</b>	<b>535</b>	<b>342</b>	<b>742</b>



**Biommm S.A.**

Individual and consolidated interim financial statements as of March 31, 2026

**b) Reconciliation of revenue (expense) from income tax and social contribution**

Reconciliation of income tax and social contribution amounts is as follows:

	Parent Company and Consolidated	
	03/31/2026	03/31/2025
Income (loss) before income taxes	11,706	(12,625)
Nominal rate (IR/CS)	34%	34%
	<b>(3,980)</b>	<b>4,293</b>
Permanent (exclusions) additions:		
Equity in net income of subsidiaries	13	(19)
Other permanent additions and exclusions	1,953	(3,384)
	<b>(2,014)</b>	<b>890</b>
Deferred income tax and social contribution	1,464	890
Current income tax and social contribution	(3,478)	-
Effective rate	17%	-7%

**18. Contingencies**

The Company formed provision for lawsuits for which the expectation of loss is considered probable and for which there is a present obligation at the balance sheet date.

	Parent Company and Consolidated	
	Labor	Total
Balance at December 31, 2025	3,036	3,036
Formations	111	111
Reversals	-	-
Balance at March 31, 2026	<b>3,147</b>	<b>3,147</b>

	Parent Company and Consolidated	
	Labor	Total
Balance at December 31, 2024	3,102	3,102
Formations	2,209	2,209
Reversals	(1,109)	(1,109)
Balance at March 31, 2025	<b>4,202</b>	<b>4,202</b>



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

On March 31, 2026, the total amount involved in labor lawsuits with probable loss expectation, according to the Company’s assessment, is R\$ 3,147 (R\$ 3,036 on December 31, 2025). As of March 31, 2026, the Company has no tax or civil lawsuits assessed as probable losses.

As of March 31, 2026, the Company also had:

- i. labor lawsuits, which correspond mainly to claims for overtime, severance pay, wages, vacation pay and commissions, whose risk of loss was classified as possible, totaling R\$ 668 (R\$ 785 on December 31, 2025).
- ii. administrative tax lawsuits, which correspond to lawsuits within the scope of the Secretary of the State Treasury of Minas Gerais, whose risk of loss was classified as possible, in the amount of R\$ 164 (R\$ 164 as of December 31, 2025).

**19. Long-term incentive**

On June 29, 2023, the Annual General Meeting approved the Company’s Long-Term Incentive and Retention Program for statutory officers and employees who are considered key professionals for the Company and who are appointed and approved by the Company’s Board of Directors. The Plan is administered by the Company’s Board of Directors, subject to the limitations set out in the Plan.

Under the Plan, beneficiaries will be granted Phantom Shares, free of charge, 30% of which are linked to the conditions of remaining with the Company, and 70% related to performance according to indicators defined and approved by the Board of Directors.

The plan provides for the settlement of the Phantom Shares in cash. Thus, amounts payable to beneficiaries are recognized as liabilities and presented under the caption of other non-current liabilities. The program is accounted for as an employee benefit, in accordance with IAS 19, with the expense recognized over the vesting period, based on the conditions established in the Plan.

The Phantom Shares were granted to eligible executives of the Company using a Phantom Share Grant Agreement, subject to compliance with the following vesting conditions:

- “Phantom Shares” retention: Condition of Permanence in the Company at the end of four years from the date of grant;
- Phantom Shares Performance: Annual compliance with result indicators determined by the Board of Directors, calculated at the end of the 4<sup>th</sup> year from the grant, with the possibility of offsetting the achievement of targets between the 4 years of the plan.

Assumptions	1 <sup>st</sup> grant	2 <sup>nd</sup> grant	3 <sup>rd</sup> grant	4 <sup>th</sup> grant
Average fair value on grant date	5.69	6.38	9.69	6.31
Number of Phantom Shares Retention	162,325	126,968	112,177	194,816
Number of Phantom Shares Performance	378,760	296,259	261,747	454,572
Fair value as of March 31, 2026	7.60	7.60	7.60	7.60



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

On March 31, 2026, the impact on the income (loss) in the personnel expenses line was R\$ 172 (R\$ 633 as of March 31, 2025).

## 20.Shareholders' equity

### a) Capital

The changes in the Company's capital over the last two years were approved at a Board of Directors' meeting through the issue of new common, book-entry shares with no par value and are shown below:

Event	Approval date	Number of shares (*)	Capital
<b>Balance at December 31, 2025</b>		136,841,532	957,501
Capital increase	March 26, 2026	10,952	153
<b>Balance at March 31, 2026</b>		<b>136,852,484</b>	<b>957,654</b>

(\*) Quantity of common shares in whole numbers.

As of March 31, 2026, the Company's authorized and paid-up capital is R\$ 957,654.

On March 26, 2026, the Company concluded and ratified a capital increase of R\$ 153 with the subscription and total payment of 10,952 (ten thousand nine hundred and fifty-two) common, book-entry shares with no par value. Thus, the capital went from R\$ 957,501 to 957,654 divided into 136,852,484 (one hundred and thirty-six million, eight hundred and fifty-two thousand, four hundred and eighty-four) common, book-entry shares with no par value.

As of March 31, 2026, the main Company's shareholders were: Cartago Fundo de Investimento Financeiro em Ações (25.86% of shares), BTG/LAB FIA (9.71% of shares), W. Mares Guia Group (8.24% of shares), Cedro Participações (8.00% of shares), TMG/IBR Group (7.25% of shares), BNDESPAR (5.12% of the shares), Gaetani Group (5.10% of the shares). The remaining shareholders hold 30.73% of the shares.

### b) Capital reserve

The reserve value is due to the subscription at a goodwill, which occurred in 2009. In addition, the reserve includes the amounts related to the Company's share-based payment plan.

### c) Tax incentive reserve

The tax incentive reserve is formed in proportion to the incentives obtained in its operations. Until March 31, 2026, the Company had a tax incentive reserve of R\$ 11,317 (R\$ 11,317 as of December 31, 2025), which, for presentation purposes only, was absorbed by the accumulated loss under the terms of Article 189 of Law 6404/76.

### d) Equity valuation adjustment



## Biommm S.A.

Individual and consolidated interim financial statements as of March 31, 2026

The differences in foreign currencies generated in the translation into the presentation currency of operations abroad are recognized as Equity valuation adjustment.

### e) Dividends

Shareholders are ensured a minimum dividend of 25% of adjusted net income for the year, calculated under the terms of the Corporate Law.

## 21.Net revenues

	Parent Company and Consolidated	
	03/31/2026	03/31/2025
Gross sales of goods	190,207	109,827
Sales taxes	(16,181)	(1,978)
Sales returns	(382)	(161)
Discounts on sales	(81,189)	(68,097)
<b>Net revenue</b>	<b>92,455</b>	<b>39,591</b>

## 22.Costs per type

	Parent Company and Consolidated	
	03/31/2026	03/31/2025
Acquisition of medicines for resale	(45,713)	(17,912)
Raw material	(6,237)	(6,552)
Packaging material product	(1,622)	(2,877)
Depreciation	(502)	(1,176)
Labor	(1,782)	(1,702)
Utilities	(741)	(1,070)
Factory general expenditures	(1,999)	(984)
	<b>(58,596)</b>	<b>(32,273)</b>

## 23.General, administrative and other expenses

	Parent Company		Consolidated	
	03/31/2026	03/31/2025	03/31/2026	03/31/2025
Marketing, advertising and event expenses	(2,009)	(855)	(2,009)	(855)
Personnel expenditures	(10,404)	(9,685)	(10,404)	(9,685)
Depreciation and amortization	(872)	(817)	(883)	(817)



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

Outsourced services	(5,613)	(4,110)	(5,707)	(4,201)
Infrastructure expenditures	(1,381)	(1,000)	(1,381)	(1,000)
Maintenance expenditures	(27)	(39)	(27)	(39)
Travel expenses	(963)	(862)	(963)	(862)
Taxes, contributions and rates	(749)	(1,001)	(749)	(1,001)
Other expenses	(725)	(1,694)	(725)	(1,694)
	<b>(22,743)</b>	<b>(20,063)</b>	<b>(22,848)</b>	<b>(20,154)</b>
Sales expenses	(9,474)	(7,230)	(9,485)	(7,230)
General and administrative expenses	(12,017)	(10,319)	(12,111)	(10,410)
Other expenses	(1,413)	(2,514)	(1,413)	(2,514)
Net reversals through impairment loss on accounts receivable	161	-	161	-
Total	<b>(22,743)</b>	<b>(20,063)</b>	<b>(22,848)</b>	<b>(20,154)</b>

## 24. Financial revenues and expenses

	Parent Company		Consolidated	
	03/31/2026	03/31/2025	03/31/2026	03/31/2025
Financial revenues:				
Interest on interest earning bank deposits	2,092	3,292	2,210	3,442
Financial discounts received	191	18	191	19
Exchange-rate change	8,418	7,420	8,418	7,420
	<b>10,701</b>	<b>10,730</b>	<b>10,819</b>	<b>10,881</b>
Financial expenses:				
Interest on loans	(2,137)	(2,745)	(2,137)	(2,745)
Interest payable	(123)	(159)	(123)	(162)
Bank fees and IOF	(872)	(675)	(872)	(675)
Exchange-rate change	(6,992)	(7,088)	(6,992)	(7,088)
	<b>(10,124)</b>	<b>(10,667)</b>	<b>(10,124)</b>	<b>(10,670)</b>
Total	<b>577</b>	<b>63</b>	<b>695</b>	<b>211</b>



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

## 25. Earnings (loss) per share

### a) Basic

Basic earnings (losses) per share are calculated by dividing income (loss) attributable to Company's shareholders by the weighted average number of outstanding common shares during the period.

	03/31/2026	03/31/2025
Income (loss) for the year	9,692	(11,735)
Weighted average number of shares issued - common (thousands)	136,852	121,745
Earnings (loss) per share (in R\$)	<b>0.07</b>	<b>(0.10)</b>

### b) Diluted

Diluted earnings (losses) per share are calculated by dividing income (loss) attributable to Company's shareholders by the weighted average number of outstanding common shares during the period, plus stock options granted to stock option plan beneficiaries.

	03/31/2026	03/31/2025
Income (loss) for the year	9,692	(11,735)
Weighted average number of shares issued - common (thousands)	137,341	122,234
Earnings (loss) per share (in R\$)	<b>0.07</b>	<b>(0.10)</b>

## 26. Financial instruments and risk management

### a) Financial risk factors

The Company is affected by the Brazilian economic situation, exposing it to market risks such as exchange rates, interest rates, and credit risk (liquidity risk). The Company's financial risk management focuses on minimizing potential adverse market effects.

The Company did not use derivative instruments in the periods ended March 31, 2026 and 2025.

### b) Market risk

The market risk is the risk that the fair value of future cash flows of a financial instrument will float due to changes in market prices. The main market risks affecting the Company are: foreign exchange and interest rate risk.

#### (i) Foreign exchange risk

The Company's foreign exchange exposure involves market risks associated with exchange-rate fluctuations of the real against the U.S. dollar and the euro. The Company's future commitments in foreign currency include payments to foreign suppliers and related parties.

In the event of a devaluation of the real against the foreign currencies to which the commitments are pegged,



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

the Company may incur an increase of these commitments in reais.

The management of the Company's foreign exchange exposure considers various current and projected economic factors, as well as market conditions.

On March 31, 2026, part of the Company's financial commitments (suppliers, loans and related parties), which have already been contracted, are pegged to the U.S. dollar and the euro, totaling on this date US\$ 17,222 and EUR 451, respectively. The corresponding amounts in reais were R\$ 89,888 and R\$ 2,710, respectively, using the closing exchange rate on March 31, 2026, of R\$ 5.22 (reais per dollar) and R\$ 6.01 (reais per euro).

	03/31/2026		Consolidated 12/31/2025	
	Foreign currency	Reais	Foreign currency	Reais
In US dollars				
Cash and cash equivalents available abroad	7	37	6	36
Bank deposits and interest earning bank deposits	4,818	25,147	4,000	22,007
Advance to supplier	465	2,428	2,401	13,213
Supplier	(17,464)	(91,152)	(9,371)	(51,565)
Loans	(2,424)	(12,652)	(2,367)	(13,026)
Related parties	(2,624)	(13,696)	(2,624)	(14,441)
Net cash in US dollars	<b>(17,222)</b>	<b>(89,888)</b>	<b>(7,955)</b>	<b>(43,776)</b>
In Euros				
Advance to suppliers	451	2,710	179	1,157
Supplier	-	-	(3)	(22)
Net cash in Euros	<b>451</b>	<b>2,710</b>	<b>176</b>	<b>1,135</b>

A reasonably possible appreciation (devaluation) of reais (R\$), USD, EUR against all currencies on March 31, 2026 would have affected measurement of financial instruments denominated in foreign currency and affected shareholders' equity and income (loss) at amounts shown below. The analysis considers that all the remaining variables, especially interest rates, will be constant and any impact in forecast of sales and purchase will be ignored.



**Biommm S.A.**
*Individual and consolidated interim financial statements as of March 31, 2026*

	Income (loss) for the year		Consolidated Shareholders' equity	
	Valuation	Devaluation	Valuation	Devaluation
	3.46%	-3.46%	3.46%	-3.46%
USD	(596)	596	-	-
Euro	(16)	16	-	-
<b>Net foreign exchange exposure as of March 31, 2026</b>	<b>(611)</b>	<b>611</b>	<b>-</b>	<b>-</b>

- For the scenarios on March 31, 2026, in US\$ and €, the rates estimated by the Focus Report of April 17, 2026, and Bloomberg were considered, respectively.
- Considered scenarios of net liability exposure. For the Dollar (USD), a scenario of depreciation of the real was projected, while for the Euro (EUR) the appreciation of the local currency was considered, reflecting the Company's negative net position in these currencies as of March 31, 2026.

*(ii) Interest rate risk*

Interest rate risk is the risk that the fair value of cash flows or financial instruments will fluctuate due to changes in market interest rates.

The Company's financial debt as of March 31, 2026, is mainly composed of floating-rate operations, indexed to TJLP in the contract signed with FINEP and to TLP in the contracts maintained with BDMG and BNDES. Regarding the financing with FAPEMIG, the debt has a fixed rate remuneration.

Considering the historically low volatility of the TJLP, Management understands that the Company's exposure to variations in this rate is not significant. As for the liabilities indexed to the TLP, the exposure is mainly related to the variation of the IPCA, a component that influences the adjustment of this rate.

The table below presents the sensitivity analysis for possible changes in the interest rates applicable to the Company's financial debts. The exposure value corresponds to the estimated amount of disbursement associated with the payment of obligations subject to floating rates.

The projections used were based on information from an external source, specifically the Focus Bulletin, considering the expectation of IPCA for the end of the next year.

Indicators	Exposure - 03/31/2026	Valuation	Devaluation
		15.00%	-15.00%
Loans linked to the IPCA	93,694	2,577	(2,577)
Securities payable linked to the IPC	15,517	427	(427)

The Company has local interest earning bank deposits linked to floating-rate interest, in this case, the CDI (Interbank Deposit Certificate).

Among the Company's interest earning bank deposits, on March 31, 2026, a total of R\$ 1,255 was invested in fixed-income operations, including CDBs (Bank Deposit Certificates) and CPRs (Rural Product Bills), with daily liquidity in first-tier banks, and therefore classified as cash equivalents. In addition, the Company has short- and long-term investments of R\$ 30,144 relating to bank guarantees for the benefit of guarantees with FAPEMIG, FINEP, BDMG and FINEM, as detailed in Note 5.



**Biommm S.A.**

Individual and consolidated interim financial statements as of March 31, 2026

Type – ONSHORE	Net balance	
	03/31/2026	12/31/2025
CDB - ST - domestic currency	2,048	14,317
CDB - LT - domestic currency	20,657	14,738
<b>Total</b>	<b>22,705</b>	<b>29,055</b>

The table of the statement of sensitivity analysis of financial instruments is presented below to show the balance of financial assets, calculated at a rate that covers only the exchange-rate change and keeps the other variables constant.

Indicators	Exposure - 03/31/2026	Valuation	Devaluation
Interest earning bank deposits	22,705	3.46% 786	-3.46% (786)

(\*) Source of indexes: BACEN Focus report as of April 17, 2026.

This sensitivity analysis aims to measure the impact of changes in market variables on the Company’s financial instruments, considering all other market indicators to be constant. These amounts, when settled, may differ from those shown due to the estimates used in their preparation.

**c) Credit and liquidity risk**

*(i) Credit risk*

The credit risk arises from cash and cash equivalents, deposits in banks, financial institutions and balances with related parties. The Company invests its funds with financial institutions rated as top-tier, mostly in the BBB+ to AAA categories, subject to authorization from the Financial Executive Board.

The Company applies the simplified approach of IFRS 9/CPC 48 to measure expected credit losses considering a provision for expected losses over the useful life of all trade accounts receivable. The Credit Analysis area evaluates the client’s creditworthiness by taking into account their financial position, past experience and other factors.

Individual risk limits are determined with basis on internal or external classifications in accordance with limits determined by the Company. The use of credit limits is regularly monitored.

The maximum exposure to credit risk on the reporting date is the book value of securities classified as cash equivalents, interest earning bank deposit, bank deposits, accounts receivable and financial institutions, and balances with related parties on the balance sheet date.

*(ii) Liquidity risk*

Liquidity risk management considers liquidity requirements’ evaluation to ensure that the Company has



## Biommm S.A.

Individual and consolidated interim financial statements as of March 31, 2026

sufficient cash to comply with its expenses and investments, as well as debt payment.

The funds maintained by the Company are invested in checking accounts with incidence of interest, term deposits and short-term deposits, choosing instruments with appropriate maturities or liquidity sufficient to provide sufficient margin as determined by the above predictions.

The Company's Management is responsible for managing liquidity risks to ensure compliance with its obligations. The Company manages liquidity risk by maintaining the lines of loans reported in Note 14 and through private equity calls made in recent years, and constantly monitors forecast cash flows.

Consolidated	Consolidated				
	Book value as of 03/31/2026	Contractual flow	Up to 1 year	1-3 Years	>03 years
Suppliers	111,548	111,548	111,548	-	-
Securities payable	15,681	18,203	1,582	3,324	13,297
Related parties	13,769	13,769	-	-	13,769
Loans	89,900	103,068	58,978	44,090	-
Lease liabilities	494	604	487	117	-
<b>Total</b>	<b>231,392</b>	<b>247,192</b>	<b>172,595</b>	<b>47,531</b>	<b>27,066</b>

### (iii) Fair value estimate

It is assumed that the balances of cash and cash equivalents, recorded at book value, are close to their fair values, due to the turnover of their use. Related parties, suppliers, advances to suppliers, notes payable and lease liabilities are measured at amortized cost and are stated at their contractual amounts.

	03/31/2026	
	Parent Company	
	Book value	Fair value
Liabilities		
Loans and financing	89,900	87,846

## d) Fair value hierarchy

Financial instruments recorded at fair value are presented as the table below:

	03/31/2026					
	Parent Company			Consolidated		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
Assets						
Interest earning bank deposits	21,450	-	-	21,450	-	-
	12/31/2025					
	Parent Company			Consolidated		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
Assets						
Interest earning bank deposits	25,850	-	-	35,621	-	-

## 27. Transactions that do not involve cash or cash equivalents



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

The Company carried out the following operating and investment activities not involving cash, so these are not reflected in the statement of cash flows:

	03/31/2026	03/31/2025
Offset of taxes payable with recoverable taxes	6,106	1,172
Additions and remeasurements in right of use	17	-
	<b>6,123</b>	<b>1,172</b>

**28. Subsequent events**

a. Corporate Reorganization and Settlement of Investment Fund

On April 28, 2026, the Company was notified about the settlement of Fundo de Investimento em Participações Multiestratégia Cartago, which held 25.86% of Biommm’s capital. As a result of this process, the shares were distributed directly to the fund’s unitholders in proportion to their equity interests. On the same date, Alaska Asset Management consolidated its position as a reference shareholder by acquiring all the shares previously linked to the fund, reaching 26.15% interest on the Company’s total capital. Furthermore, Banco de Brasília (BRB) and Cedro Participações carried out the partial disposal of the shares received, now holding 3.25% and 0.23% of the capital, respectively.

After stock trading on 04/27, the Company’s new shareholding position was as follows: Alaska Investimentos (26.15% of the shares), BTGP Gestão (12.20% of the shares), WMG Group (8.24% of the shares), TMG/IBR (7.25% of the shares), BNDESPAR (5.12% of the shares), Gaetani Group (5.10% of the shares). The remaining shareholders hold 35.94% of the shares.

\* \* \*



**Biommm S.A.**

*Individual and consolidated interim financial statements as of March 31, 2026*

## **Board of Directors**

Cláudio Luiz Lottenberg  
Walfrido Silvino dos Mares Guia Neto  
Eduardo Augusto Buarque de Almeida  
Ítalo Aurélio Gaetani  
André Capistrano Emrich  
João Paulo Vieira Capobianco  
Luiz Alves Paes de Barros  
Thiago Fiuza Camargos Guelber de Barros Vieira

## **Executive Board**

Guilherme Maradei  
Marcelo Sáfadi Alvares  
Francisco Carlos Marques de Freitas  
Alexandre Bernardes Gonçalves  
Luciano da Silva Machado

## **Responsible technicians**

Nayara Rodrigues de Souza Cruz  
Accountant CRC: MG- 118096/O-5  
Accountant

Bernardo Vimieiro Romani  
Accountant CRC: MG-106313/O-6  
Controller

